INS and Insulin resistance: Therefore, in this clinical trial, our purpose is to test the central hypothesis that individuals with SCI and with insulin resistance, untreated type 2 diabetes or impaired glucose tolerance who follow a LC/HP diet will show improvements in clinically important metrics of metabolic function (glucose tolerance, insulin sensitivity, β-cell function), body composition (increase in lean mass and decrease in total and visceral fat mass), the composition of gut bacteria, and quality of life.